Nav: Home

Hair loss and prostate drug linked to persistent erectile dysfunction in men

March 09, 2017

  • In young men, prolonged exposure to finasteride (Propecia) posed a higher risk of persistent erectile dysfunction than any other risk factor
  • Some men may not be able to have normal erections for months or years, even after stopping finasteride or dutasteride.
  • Finasteride (Propecia, Proscar) is sometimes given to regrow hair or to shrink prostate
  • Dutasteride (Avodart, Jalyn) is sometimes given to men to shrink prostate
CHICAGO --- Men with longer exposure to the drugs finasteride and dutasteride had a higher risk of getting persistent erectile dysfunction than men with less exposure, reports a new Northwestern Medicine study. The persistent erectile dysfunction continued despite stopping these drugs, in some cases for months or years.

Among young men, prolonged exposure to the drugs posed a greater risk of persistent erectile dysfunction (PED) than all other assessed risk factors. This means there is a stronger relationship between taking these drugs and having PED than having diabetes, hypertension or smoking, which are other risk factors.

Erectile dysfunction is difficulty achieving and maintaining a sufficient erection to have sex. Persistent erectile dysfunction continued despite stopping the drug and continued despite taking sildenafil (Viagra) or similar drug.

Prior to the new study, there was no strong evidence that finasteride and dutasteride cause sexual problems that continue after men stop taking them. There also was no strong evidence that taking these drugs for a longer time increases the chance of experiencing sexual problems.

"Our study shows men who take finasteride or dutasteride can get persistent erectile dysfunction, in which they will not be able to have normal erections for months or years after stopping finasteride or dutasteride," said lead study author Dr. Steven Belknap, a research assistant professor of dermatology at Northwestern University Feinberg School of Medicine.

Finasteride and dutasteride are drugs that are male hormone blockers. These drugs block the conversion of testosterone to its more active form, 5 alpha dihydrotestosterone.

Finasteride is prescribed to some men with prostate enlargement or baldness. Dutasteride is prescribed to some men with prostate enlargement.

Propecia and Proscar are brand names for finasteride. Avodart is a brand name for dutasteride. Jalyn is a combination drug containing dutasteride and tamsulosin.

The new findings of an association between debilitating sexual dysfunction and exposure to finasteride or dutasteride should be of particular interest to prescribers and patients considering medical management of androgenic alopecia (hair loss) or symptomatic treatment of enlarged prostate, Belknap said.

The study will be published March 9 in the journal PeerJ.

Among the men studied, 167 of 11,909 (1.4 percent) developed persistent erectile dysfunction that continued for a median of 1,348 days after stopping the drugs.

Young men under 42 years old who had more than 205 days of finasteride or dutasteride exposure had 4.9-fold higher risk of persistent erectile dysfunction than men with shorter exposure.

The study evaluated data from 11,909 men for PED. Eligible subjects for evaluation for new PED were men 16 to 89 years old with at least one clinical encounter and one diagnosis from January 1992 to September 2013.

The study was made possible by the Northwestern Medicine Electronic Data Warehouse, an electronic medical record data repository for patients of Northwestern Medicine.

The findings follow a 2015 JAMA Dermatology study by Belknap showing published reports of clinical trials provide insufficient information to adequately establish the safety of finasteride for treatment of hair loss in men. This was the first meta-analysis of the quality of safety reporting in clinical trials of finasteride for treatment of male hair loss.
-end-
The study was supported by grants 5R01CA102713-04 and 1R01 CA125077-01A1 from the National Cancer Institute and grants UL1TR001422, UL1TR000150 and UL1RR025741 from the National Center for Advancing Translational Sciences, all of the National Institutes of Health. The Post-Finasteride Syndrome Foundation also supported the study.

Northwestern University

Related Erectile Dysfunction Articles:

Concussions linked to erectile dysfunction in former NFL players
Former NFL players reporting concussion symptoms following head injury more likely to report erectile dysfunction and low testosterone levels.
Erectile dysfunction associated with lower work productivity in men
Erectile dysfunction (ED) was linked with loss of work productivity and with lower health-related quality of life in an International Journal of Clinical Practice study of more than 52,000 men from eight countries.
The global prevalence of erectile dysfunction
A review of published studies found that estimates for the global prevalence of erectile dysfunction vary widely, ranging from 3% to 76.5%.
Improved procedure for cancer-related erectile dysfunction
Melbourne surgeons have modified a minimally invasive technique to help men regain erectile function lost after prostate cancer surgery.
New discovery provides key to side effects caused by erectile dysfunction drugs
Study reveals several features of PDE6 that were previously unseen.
Convincing evidence that type 2 diabetes is a cause of erectile dysfunction
Evidence that type 2 diabetes is a cause of erectile dysfunction has been found in a large-scale genomic analysis.
First genetic risk factor for erectile dysfunction identified
For the first time, a team of researchers has found a specific place in the human genome that raises a person's risk of erectile dysfunction.
Genetic risk factor for erectile dysfunction identified
In a new study that ultimately analyzed the genomes of nearly a quarter of a million men, a research team including UC San Francisco scientists has discovered that variants at a single site on Chromosome 6 are associated with a significantly higher risk of developing erectile dysfunction (ED).
Irreversible damage to color vision linked to popular erectile dysfunction drug
In a first-of-its-kind study, Mount Sinai researchers have shown that color vision problems caused by retinal damage on a cellular level can result from a high dose of sildenafil citrate, the popular erectile-dysfunction medication sold under the brand name Viagra.
Erectile dysfunction drugs may help treat many other conditions
A new British Journal of Pharmacology review examines how phosphodiesterase-5 (PDE5) inhibitors, which were originally approved to treat erectile dysfunction, are finding clinical uses for a wide variety of conditions.
More Erectile Dysfunction News and Erectile Dysfunction Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.